Emboline is a privately held medical device company focusing on minimizing embolic complications during structural heart interventions. Its lead product, the Emboliner® Embolic Protection System, captures and removes embolic debris released during transcatheter aortic valve replacement and similar procedures, aiming to provide both cerebral and systemic protection. The company recently completed enrollment of the PROTECT H2H IDE clinical trial assessing the Emboliner and plans to present trial data at the American College of Cardiology Annual Scientific Session on March 29, 2026. With an extensive intellectual-property portfolio covering full-body embolic filtration and aortic deflection, Emboline is positioning itself as a comprehensive embolic-protection platform provider. The firm is now preparing regulatory submissions and expects to launch commercially in the United States and Europe later in 2026. Proceeds from its latest financing will fund these commercialization efforts and continued product development. The Emboliner remains investigational and is not yet available for sale, and no revenue or user metrics have been publicly disclosed.

Total raised

$100M

Funding rounds

6

Latest round

Equity

Latest activity

Mar 2026